针对儿童异常性尿路炎的一种新疗法:局部类固醇注射
Sonia Pérez-Bertólez1, Isabel Casal-Beloy1, Oriol Martín-Solé1
1Pediatric Urology Unit, Pediatric Surgery Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Spain.
Journal of pediatric urology
|October 12, 2023
概括
局部类固醇注射 (LSI) 提供了一种有效的治疗儿科异形性尿路炎 (IU). 大多数儿童经历了完全症状的消失,证明了LSI.
科学领域:
- 儿科泌尿外科 儿科泌尿外科
- 炎症条件 炎症条件
背景情况:
- 异形性尿路炎 (IU) 在没有标准化治疗方法的情况下提出了管理挑战.
- 目前对儿科IU的治疗选择有限,并且通常是无效的.
研究的目的:
- 评估局部类固醇注射 (LSI) 作为治疗儿童异常性尿路炎的疗效.
- 介绍儿童患者的结局,这些患者接受了IU的LSI.
主要方法:
- 七名儿科患者的回顾性审查,在2020年至2021年期间接受IU治疗.
- 所有患者都接受了局部类固醇注射 (LSI).
- 内部尿道切除是两个同时发生尿道狭窄的患者的辅助手术.
主要成果:
- 在7名患者中,有6名患者在LSI后实现了IU症状和迹象的完全消失.
- 其余的患者经历了显著的症状改善,尽管并没有完全缓解.
- 在研究队列中没有报告任何重大不良事件.
结论:
- 局部类固醇注射 (LSI) 似乎是一个安全有效的治疗选择,用于儿科异常性尿路炎 (IU).
- 在儿童中,LSI为现有的IU治疗提供了一个有希望的替代方案.
- 需要进一步的研究来确定LSI作为儿科IU的标准治疗方法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
173
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
173
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
136
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
136
Tonsillitis II: Management
120
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
120
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
422
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
422
Urinary Tract Infection IV: Nursing Management
17
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
17
Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152


